HRP20200964T1 - IL-ß NEUTRALIZIRAJUĆA LJUDSKA MONOKLONSKA PROTUTIJELA - Google Patents
IL-ß NEUTRALIZIRAJUĆA LJUDSKA MONOKLONSKA PROTUTIJELA Download PDFInfo
- Publication number
- HRP20200964T1 HRP20200964T1 HRP20200964TT HRP20200964T HRP20200964T1 HR P20200964 T1 HRP20200964 T1 HR P20200964T1 HR P20200964T T HRP20200964T T HR P20200964TT HR P20200964 T HRP20200964 T HR P20200964T HR P20200964 T1 HRP20200964 T1 HR P20200964T1
- Authority
- HR
- Croatia
- Prior art keywords
- binding protein
- antigen
- agent
- choice
- isolated
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title 1
- 102000025171 antigen binding proteins Human genes 0.000 claims 12
- 108091000831 antigen binding proteins Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (12)
1. Izolirani IL-1β specifični protein koji veže antigen koji sadrži sljedeće CDR-ove:
- varijabilnu regiju teškog lanca koja uključuje CDR-ove H1 = DYYWS, H2 = EIDHSGSTNINPSLKS, H3 = ASPSSGWTLDY; i
- varijabilnu regiju lakog lanca koja uključuje CDR-ove L1 = GDKLGDKFAF, L2 = LDNKRPS, L3 = YAWADTYEV.
2. Izolirani protein koji veže antigen prema patentnom zahtjevu 1, naznačen time što sadrži teški lanac i/ili laki lanac, pri čemu teški lanac sadrži QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWSWIRQPPGKGLEWIGEIDHSGSTNINPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARASPSSGWTLDYWGQGTL, i laki lanac sadrži
[image]
3. Izolirani protein koji veže antigen prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je navedeni protein protutijelo; po izboru
pri čemu je navedeno protutijelo monoklonsko, poliklonsko, bispecifično, multispecifično ili heterokonjugat; po izboru
pri čemu je navedeno protutijelo potpuno ljudsko; po izboru
pri čemu je navedeno protutijelo podtipa IgG1, podtipa IgG2, podtipa IgG4, ili podtipa IgG3; po izboru
pri čemu navedeni protein je jednostruka varijabilna domena, domensko protutijelo, ulomak koji veže antigen, imunološki učinkovit ulomak, jednolančani Fv, diatijelo ili četverovalentno bispecifično protutijelo (Tandab); po izboru
pri čemu navedeni ulomak sadrži teški lanac koji sadrži sekvencu QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWSWIRQPPGKGLEWIGEIDHSGSTNINPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARASPSSGWTLDYWGQGTL i laki lanac sadrži sekvencu
[image]
4. Izolirani protein koji veže antigen prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je protein rekombinantni; po izboru
pri čemu navedeni vezivni protein nadalje sadrži sredstvo izabrano iz skupine koja sadrži imunoadhezijsku molekulu, sredstvo za snimanje, terapeutsko sredstvo i citotoksično sredstvo; po izboru
pri čemu je navedeno sredstvo za snimanje izabrano iz skupine koja sadrži radio-oznaku, enzim, fluorescentnu oznaku, luminiscentnu oznaku, bioluminiscentnu oznaku, magnetsku oznaku, te biotin; po izboru
pri čemu je navedeno sredstvo terapeutsko ili citotoksično sredstvo izabrano iz skupine koja sadrži anti-metabolit, alkilirajuće sredstvo, antibiotik, faktor rasta, citokin, anti-angiogeno sredstvo, anti-mitotičko sredstvo, antraciklin, toksin i apoptotičko sredstvo.
5. Izolirani protein koji veže antigen prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je za uporabu za liječenje raka, upalne bolesti ili autoimune bolesti odabrane iz skupine koja sadrži artritis, upalnu bolest crijeva, Crohnovu bolest, reumatoidni artritis, giht, dijabetes, uveitis, perioidički sindrom povezan s kriopirinom i upalne akne.
6. Pripravak naznačen time što sadrži izolirani protein koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 4 i farmaceutski prihvatljiv nosač.
7. Pripravak prema zahtjevu 6, naznačen time što nadalje sadrži jedno ili više terapijskih sredstava.
8. Izolirana nukleinska kiselina koja kodira izolirani protein koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu nukleinska kiselina sadrži prvu sekvencu koja kodira varijabilnu regiju teškog lanca i drugu sekvencu koja kodira varijabilnu regiju lakog lanca navedenog proteina koji veže antigen.
9. Komplet dviju izoliranih nukleinskih kiselina koje zajedno kodiraju izolirani protein koji veže antigen prema patentnom zahtjevu 1, naznačen time što:
- prva nukleinska kiselina sadrži sekvencu koja kodira varijabilnu regiju teškog lanca navedenog proteina koji veže antigen, i
- druga nukleinska kiselina sadrži sekvencu koji kodira varijabilnu regiju lakog lanca navedenog proteina koji veže antigen.
10. Vektor naznačen time što sadrži izoliranu nukleinsku kiselinu prema zahtjevu 8, ili komplet nukleinskih kiselina prema zahtjevu 9.
11. Stanica domaćina naznačena time što sadrži izoliranu nukleinsku kiselinu prema zahtjevu 8, ili komplet nukleinskih kiselina prema zahtjevu 9, ili vektor prema zahtjevu 10.
12. Postupak za proizvodnju izoliranog proteina koji veže antigen prema bilo kojem od patentnih zahtjeva 1-4, naznačen time što obuhvaća kultiviranje stanice domaćina prema zahtjevu 11 pod odgovarajućim uvjetima i obnavljanje proteina iz nje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG2012010070 | 2012-02-13 | ||
| EP13748708.8A EP2814843B1 (en) | 2012-02-13 | 2013-02-13 | IL-ß NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES |
| PCT/SG2013/000057 WO2013122544A2 (en) | 2012-02-13 | 2013-02-13 | IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200964T1 true HRP20200964T1 (hr) | 2020-10-30 |
Family
ID=54261183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200964TT HRP20200964T1 (hr) | 2012-02-13 | 2020-06-17 | IL-ß NEUTRALIZIRAJUĆA LJUDSKA MONOKLONSKA PROTUTIJELA |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10167335B2 (hr) |
| EP (2) | EP2814843B1 (hr) |
| JP (1) | JP6383665B2 (hr) |
| CN (1) | CN105431452B (hr) |
| CY (1) | CY1123519T1 (hr) |
| DK (1) | DK2814843T3 (hr) |
| ES (1) | ES2798110T3 (hr) |
| HR (1) | HRP20200964T1 (hr) |
| HU (1) | HUE049860T2 (hr) |
| LT (1) | LT2814843T (hr) |
| PL (1) | PL2814843T3 (hr) |
| PT (1) | PT2814843T (hr) |
| RS (1) | RS60583B1 (hr) |
| SG (2) | SG11201404850SA (hr) |
| SI (1) | SI2814843T1 (hr) |
| WO (1) | WO2013122544A2 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2814843T1 (sl) | 2012-02-13 | 2020-11-30 | Agency For Science, Technology And Research | IL-beta nevtralizirajoča humana monoklonska protitelesa |
| CN106928354B (zh) * | 2017-04-25 | 2020-07-17 | 长春金赛药业有限责任公司 | 抗IL-1β单克隆抗体及其应用 |
| JP2020524694A (ja) * | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのＩＬ−１β結合性抗体 |
| CN117343173A (zh) * | 2019-03-07 | 2024-01-05 | 瑞阳(苏州)生物科技有限公司 | 人IL-1β蛋白结合分子及其编码基因和应用 |
| KR102087743B1 (ko) * | 2019-06-10 | 2020-03-12 | 을지대학교 산학협력단 | IL-1beta에 특이적으로 결합하는 항체 및 그의 용도 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| BR9508243A (pt) | 1994-07-05 | 1997-10-21 | Steeno Res Group As | Imunomoduladores |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US20030007972A1 (en) | 1999-02-24 | 2003-01-09 | Edward Tobinick | Cytokine antagonists and other biologics for the treatment of bone metastases |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| AU2004207741B2 (en) | 2003-01-24 | 2011-02-10 | Applied Molecular Evolution, Inc | Human IL-1 beta antagonists |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| ATE416190T1 (de) | 2003-07-04 | 2008-12-15 | Affibody Ab | Polypeptide mit bindungsaffinität für her2 |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| CA2552435A1 (en) | 2003-12-05 | 2005-06-23 | Compound Therapeutics, Inc. | Inhibitors of type 2 vascular endothelial growth factor receptors |
| EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| HUE029021T2 (en) | 2005-06-21 | 2017-02-28 | Xoma (Us) Llc | IL-1beta-binding antibodies and fragments thereof |
| TWI395754B (zh) * | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| RU2012119788A (ru) | 2009-10-15 | 2013-11-20 | Эбботт Лэборетриз | Связывающие il-1 белки |
| WO2012121679A1 (en) | 2011-03-09 | 2012-09-13 | Agency For Science, Technology And Research | Method of modulating phenotype of a renal cell cancer-associated monocyte or macrophage |
| TWI838039B (zh) | 2011-03-28 | 2024-04-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| SI2814843T1 (sl) | 2012-02-13 | 2020-11-30 | Agency For Science, Technology And Research | IL-beta nevtralizirajoča humana monoklonska protitelesa |
| WO2016008851A1 (en) | 2014-07-14 | 2016-01-21 | Boehringer Ingelheim International Gmbh | Anti-il-1b antibodies |
| AU2016261770B2 (en) | 2015-05-12 | 2022-06-02 | Drexel University | Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same |
| JP6878405B2 (ja) | 2015-07-29 | 2021-05-26 | ノバルティス アーゲー | Ｐｄ−１に対する抗体分子を含む組み合わせ治療 |
| US10397741B2 (en) | 2016-11-11 | 2019-08-27 | Shoreline Tracking Systems, LLC | System and method for service tracking |
| JP2020524694A (ja) | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのＩＬ−１β結合性抗体 |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
-
2013
- 2013-02-13 SI SI201331741T patent/SI2814843T1/sl unknown
- 2013-02-13 EP EP13748708.8A patent/EP2814843B1/en active Active
- 2013-02-13 ES ES13748708T patent/ES2798110T3/es active Active
- 2013-02-13 US US14/378,442 patent/US10167335B2/en active Active
- 2013-02-13 SG SG11201404850SA patent/SG11201404850SA/en unknown
- 2013-02-13 RS RS20200680A patent/RS60583B1/sr unknown
- 2013-02-13 PL PL13748708T patent/PL2814843T3/pl unknown
- 2013-02-13 JP JP2014557603A patent/JP6383665B2/ja active Active
- 2013-02-13 PT PT137487088T patent/PT2814843T/pt unknown
- 2013-02-13 LT LTEP13748708.8T patent/LT2814843T/lt unknown
- 2013-02-13 WO PCT/SG2013/000057 patent/WO2013122544A2/en active Application Filing
- 2013-02-13 EP EP20163420.1A patent/EP3736289A1/en not_active Withdrawn
- 2013-02-13 SG SG10201708562VA patent/SG10201708562VA/en unknown
- 2013-02-13 HU HUE13748708A patent/HUE049860T2/hu unknown
- 2013-02-13 CN CN201380019370.3A patent/CN105431452B/zh active Active
- 2013-02-13 DK DK13748708.8T patent/DK2814843T3/da active
-
2018
- 2018-11-15 US US16/192,537 patent/US10919962B2/en active Active
-
2020
- 2020-06-17 HR HRP20200964TT patent/HRP20200964T1/hr unknown
- 2020-06-18 CY CY20201100562T patent/CY1123519T1/el unknown
- 2020-10-01 US US17/061,194 patent/US11780913B2/en active Active
-
2021
- 2021-01-15 US US17/150,691 patent/US11702471B2/en active Active
- 2021-01-15 US US17/150,689 patent/US11912761B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105431452A (zh) | 2016-03-23 |
| EP2814843B1 (en) | 2020-03-18 |
| JP2015518368A (ja) | 2015-07-02 |
| HUE049860T2 (hu) | 2020-11-30 |
| WO2013122544A2 (en) | 2013-08-22 |
| US20190144535A1 (en) | 2019-05-16 |
| RS60583B1 (sr) | 2020-08-31 |
| US11912761B2 (en) | 2024-02-27 |
| CY1123519T1 (el) | 2022-03-24 |
| US20210024627A1 (en) | 2021-01-28 |
| US20210155686A1 (en) | 2021-05-27 |
| WO2013122544A9 (en) | 2014-10-02 |
| SG10201708562VA (en) | 2017-12-28 |
| EP3736289A1 (en) | 2020-11-11 |
| JP6383665B2 (ja) | 2018-08-29 |
| EP2814843A2 (en) | 2014-12-24 |
| WO2013122544A3 (en) | 2015-03-26 |
| US20150037248A1 (en) | 2015-02-05 |
| PT2814843T (pt) | 2020-06-18 |
| EP2814843A4 (en) | 2016-04-06 |
| ES2798110T3 (es) | 2020-12-09 |
| PL2814843T3 (pl) | 2020-11-16 |
| US20210155685A1 (en) | 2021-05-27 |
| LT2814843T (lt) | 2020-09-25 |
| US11702471B2 (en) | 2023-07-18 |
| CN105431452B (zh) | 2019-12-31 |
| SG11201404850SA (en) | 2014-09-26 |
| DK2814843T3 (da) | 2020-06-22 |
| US11780913B2 (en) | 2023-10-10 |
| US10919962B2 (en) | 2021-02-16 |
| US10167335B2 (en) | 2019-01-01 |
| SI2814843T1 (sl) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200964T1 (hr) | IL-ß NEUTRALIZIRAJUĆA LJUDSKA MONOKLONSKA PROTUTIJELA | |
| HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
| IL266893A (en) | Meditops and antibodies bind meditops and their use | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20190486T1 (hr) | Konjugirani spojevi koji sadrže cisteinska protutijela dobivena inženjeringom | |
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| JP2018504105A5 (hr) | ||
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| HRP20150965T1 (hr) | Anti-fgr3 protutijela i metode koje ih koriste | |
| HRP20211129T1 (hr) | Nukleinske kiseline koje kodiraju humana antitijela na sialyl-lewis a | |
| HRP20201259T1 (hr) | Protutijela protiv ox40 i njihova upotreba | |
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20231281T1 (hr) | Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom | |
| HRP20240767T1 (hr) | Cd3 vezujuća antitijela | |
| HRP20120611T1 (hr) | Anti-il-23p19 antitijela proizvedena genetiäśkim inžinjerstvom | |
| HRP20160702T1 (hr) | Protutijela protiv proliferirajućeg inducirajućeg liganda (april) | |
| JP2013198490A5 (hr) | ||
| HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
| JP2015535828A5 (hr) | ||
| JP2009225799A5 (hr) |